Dashboard
Poor Management Efficiency with a low ROE of 6.24%
- The company has been able to generate a Return on Equity (avg) of 6.24% signifying low profitability per unit of shareholders funds
Poor long term growth as Operating profit has grown by an annual rate -55.49% of over the last 5 years
The company has declared Negative results for the last 14 consecutive quarters
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 32 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.03
-10.35%
0.42
Total Returns (Price + Dividend) 
Natural Alternatives International, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is Natural Alternatives International, Inc. technically bullish or bearish?
As of 25 August 2025, the technical trend for Natural Alternatives International, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven by daily moving averages indicating bearish momentum and weekly Bollinger Bands also signaling a bearish trend. The Dow Theory and On-Balance Volume (OBV) both reflect a mildly bearish outlook on the weekly and monthly time frames. Despite the MACD showing mildly bullish signals on both weekly and monthly charts, the overall sentiment remains bearish due to the prevailing indicators. The stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -24.59% versus the S&P 500's 12.22%, and a one-year return of -49.46% compared to the S&P 500's 17.14%....
Read MoreIs Natural Alternatives International, Inc. overvalued or undervalued?
As of 13 February 2024, the valuation grade for Natural Alternatives International, Inc. has moved from expensive to risky, indicating a deteriorating outlook. The company appears to be overvalued given its significant losses and negative return metrics. Key ratios include a Price to Book Value of 0.42, an EV to Sales ratio of 0.28, and an EV to EBITDA of -7.72, all of which suggest that the company's valuation does not align well with its financial performance. In comparison to its peers, Natural Alternatives International, Inc. has a much lower EV to EBITDA ratio than Chromadex Corp. at 36.5633 and USANA Health Sciences, Inc. at 4.7297, both of which are categorized as expensive. The company's stock has underperformed significantly against the S&P 500, with a 1-year return of -49.46% compared to the index's 17.14%, reinforcing the notion of its overvaluation....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 8 Schemes (13.6%)
Held by 6 Foreign Institutions (0.68%)
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
QoQ Growth in quarter ended Mar 2025 is -15.59% vs 2.41% in Dec 2024
QoQ Growth in quarter ended Mar 2025 is 0.00% vs -10.00% in Dec 2024
Annual Results Snapshot (Consolidated) - Jun'24
YoY Growth in year ended Jun 2024 is -27.52% vs -6.55% in Jun 2023
YoY Growth in year ended Jun 2024 is -388.00% vs -76.64% in Jun 2023






